Antimyeloperoxidase antibody is a biomarker for progression of diabetic retinopathy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16370%2F16%3A43874484" target="_blank" >RIV/62157124:16370/16:43874484 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.jdiacomp.2016.01.010" target="_blank" >http://dx.doi.org/10.1016/j.jdiacomp.2016.01.010</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jdiacomp.2016.01.010" target="_blank" >10.1016/j.jdiacomp.2016.01.010</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Antimyeloperoxidase antibody is a biomarker for progression of diabetic retinopathy

Popis výsledku v původním jazyce

Aim: To study the correlation between serum antimyeloperoxidase (MPO) antibody levels with severity of diabetic retinopathy (DR). Methods: Study subjects included 60 consecutive cases of type 2 diabetes mellitus (DM): no diabetic retinopathy (NODR, n = 20); nonproliferative DR (NPDR, n = 20); proliferative DR (PDR, n = 20) and 20 healthy controls. Best corrected visual acuity (BCVA) was measured on logMAR scale. Serum anti-MPO antibody levels were evaluated using ELISA IgG kit. Serum urea and creatinine was measured using standard protocol. Data were analysed statistically. Results: Mean serum anti-MPO antibody (RU/ml) was 16.94 +/- 4.85 in controls, 17.66 +/- 4.78 in NODR, 21.51 +/- 5.27 in NPDR and 37.27 +/- 11.92 in PDR groups. On ANOVA, significant difference in visual acuity was found among the study groups (F = 73.46, p < 0.001). Serum anti-MPO antibody was correlated significantly with decrease in visual acuity (F = 48.40, p < 0.001), increase in serum urea (F = 128.13, p < 0.001) and creatinine (F = 77.10, p < 0.001). Conclusion: Increase in serum anti-MPO antibody levels correlate with increased severity of DR. Serum anti-MPO antibody may be a noteworthy biochemical marker for progression of retinopathy from nonproliferative to proliferative stage.

Název v anglickém jazyce

Antimyeloperoxidase antibody is a biomarker for progression of diabetic retinopathy

Popis výsledku anglicky

Aim: To study the correlation between serum antimyeloperoxidase (MPO) antibody levels with severity of diabetic retinopathy (DR). Methods: Study subjects included 60 consecutive cases of type 2 diabetes mellitus (DM): no diabetic retinopathy (NODR, n = 20); nonproliferative DR (NPDR, n = 20); proliferative DR (PDR, n = 20) and 20 healthy controls. Best corrected visual acuity (BCVA) was measured on logMAR scale. Serum anti-MPO antibody levels were evaluated using ELISA IgG kit. Serum urea and creatinine was measured using standard protocol. Data were analysed statistically. Results: Mean serum anti-MPO antibody (RU/ml) was 16.94 +/- 4.85 in controls, 17.66 +/- 4.78 in NODR, 21.51 +/- 5.27 in NPDR and 37.27 +/- 11.92 in PDR groups. On ANOVA, significant difference in visual acuity was found among the study groups (F = 73.46, p < 0.001). Serum anti-MPO antibody was correlated significantly with decrease in visual acuity (F = 48.40, p < 0.001), increase in serum urea (F = 128.13, p < 0.001) and creatinine (F = 77.10, p < 0.001). Conclusion: Increase in serum anti-MPO antibody levels correlate with increased severity of DR. Serum anti-MPO antibody may be a noteworthy biochemical marker for progression of retinopathy from nonproliferative to proliferative stage.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

CE - Biochemie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of diabetes and its complications

ISSN

1056-8727

e-ISSN

—

Svazek periodika

30

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

5

Strana od-do

700-704

Kód UT WoS článku

000374916200022

EID výsledku v databázi Scopus

—